A Double-blind, Randomized, Placebo-controlled, Dose-ranging, Single-dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DBPR108 in Healthy Male Subjects.

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Dose-ranging, Single-dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DBPR108 in Healthy Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2014

At a glance

  • Drugs DBPR 108 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 07 Feb 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 27 Jul 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01650324).
    • 27 Jul 2012 Official title amended, planned number of patients 54 added and additional lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top